Phage-Derived Cell Wall Hydrolases for Selective Staphylococcus Lysis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic approaches for Staphylococcus infections, particularly those caused by antibiotic-resistant strains, are ineffective and often harm commensal bacteria, leading to unmet needs for new treatments that can selectively target and eliminate pathogenic Staphylococcus species without disrupting the skin microbiome.

Innovation Solution

Development of recombinant proteins comprising enzymatically active domains (EADs) from Staphylococcus phage proteins, combined with cell wall binding domains (CBDs), which form chimeric cell wall hydrolases (CWHs) that specifically target and lyse Staphylococcus species, maintaining the balance of the skin microbiome.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics or chemicals like benzoyl peroxide are used to treat bacterial infection, then pathogenic Staphylococcus species are killed, but commensal bacterial populations are also negatively affected

Engineering Contradiction:

Improveeffectiveness against pathogenic StaphylococcusVSAvoidharm to commensal bacteria

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The phage protein is divided into two functional segments: a cell wall binding domain (CBD) that specifically recognizes and binds to Staphylococcus cell wall components, and an enzymatically active domain (EAD) that performs the lytic function. This segmentation allows the CBD to provide species-specific targeting while the EAD delivers the therapeutic effect, ensuring that only Staphylococcus cells are affected and commensal bacteria are spared.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The chimeric CWH is designed with localized functional domains: the CBD region confers specific binding affinity to Staphylococcus cell walls through recognition of particular peptidoglycan structures, while the EAD region provides the enzymatic lytic activity. This local differentiation of function ensures that the therapeutic action is concentrated on the target pathogen without affecting other bacterial populations.

Inventive Principle:

Principle #3Local quality

2Reliability

If conventional antibiotics are used to treat antibiotic-resistant Staphylococcus strains, then treatment effectiveness is maintained, but the problem of antibiotic resistance makes them very difficult to manage

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidresistance management flexibility

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention replaces the chemical mechanism of conventional antibiotics with a biological mechanism based on phage-derived proteins. Instead of using small-molecule antibiotics that can be easily resisted through target modification, the chimeric CWHs use a two-domain protein system where the CBD provides specific recognition and the EAD provides enzymatic lysis, representing a fundamental substitution of the therapeutic mechanism that bypasses traditional antibiotic resistance pathways.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The chimeric CWH is a composite protein structure combining domains from different sources: the CBD is derived from Staphylococcus-specific cell wall hydrolases or phage proteins, while the EAD is derived from lytic enzymes. This composite structure creates a novel therapeutic agent with properties that differ fundamentally from conventional antibiotics, providing activity against resistant strains through a different mechanism of action.

Inventive Principle:

Principle #40Composite materials

3Productivity

If high lytic activity is achieved against Staphylococcus species, then therapeutic effectiveness is improved, but selectivity against commensal bacteria must be maintained

Engineering Contradiction:

Improvelytic activityVSAvoidlack of selectivity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The CBD acts as an intermediary that mediates the interaction between the chimeric CWH and the target cell wall. It specifically recognizes and binds to Staphylococcus cell wall components (such as peptidoglycan structures) before the EAD is positioned to exert its lytic effect, ensuring that high lytic activity is directed only at the intended target and not at commensal bacteria.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The chimeric CWHs demonstrate high lytic activity against Staphylococcus species, particularly Staphylococcus aureus, while exhibiting minimal activity against commensal bacteria, effectively treating conditions like atopic dermatitis and acute radiation dermatitis without disrupting the skin microbiome.

Implementation Method 1

enzymatically active domains (EADs) from Staphylococcus phage proteins... chimeric cell wall hydrolases (CWHs) that specifically target and lyse Staphylococcus species

Methodology Applied

Scientific EffectEnzymatic hydrolysis: Hydrolysis

Data Source

PatentUS20260078152A1Enzymatically active domains from Anti-staphylococcal phage proteins

Publication Date: 2026.03.19 TOPAZ BIOSCIENCES INC

AI summary

The present disclosure relates to novel enzymatically active domains from Staphylococcus phage proteins. The disclosure also relates to cell wall hydrolases comprising these enzymatically active domains and uses thereof in the treatment of infection with Staphylococcus sp.